Compositions and methods for the treatment of fat infiltration in muscle
This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
1. A method for treating or reducing muscle atrophy, comprising administering to a subject an effective amount of composition comprising:
a) a leucine (L)-amino acid entity chosen from L-leucine, oxo-leucine, -hydroxy-methylbutyrate (HMB), isovaleryl-CoA, or N-acetyl-leucine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
b) an arginine (R)-amino acid entity chosen from L-arginine, argininosuccinate, agmatine, creatine, or N-acetyl-arginine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
c) a glutamine (Q)-amino acid entity chosen from L-glutamine, carbamoyl-P, or N-acetyl-glutamine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
d) N-acetylcysteine (NAC) or a salt thereof, a dipeptide or salt thereof, or a combination of any of the aforesaid; and
e) an essential amino acid (EAA)-entity chosen from one, two, three, or four of:
i) a histidine (H)-amino acid-entity chosen from L-histidine, histidinol, histidinal, ribose-5-phosphate, carnosine, histamine, urocanate, or N-acetyl-histidine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
ii) a lysine (K)-amino acid-entity chosen from L-lysine, diaminopimelate, trimethyllysine, saccharopine, or N-acetyl-lysine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
iii) a phenylalanine (F)-amino acid-entity chosen from L-phenylalanine, phenylpyruvate, or N-acetyl-phenylalanine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid; or
iv) a threonine (T)-amino acid-entity chosen from L-threonine, oxo-butyrate, or N-acetyl-threonine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
wherein at least one of the leucine amino acid entity, the arginine amino acid, the glutamine amino acid entity, or one, two, three, or all of the EAA amino acid entities is a free amino acid,
wherein at least 50 wt. % of the total dry wt. of the composition is one or more amino acid entities in free form, and
wherein the total wt. % of (a)-(e) is greater than the total wt. % of other amino acid entities in the composition.
2. A method of activating muscle protein synthesis, reducing muscle protein wasting, or both, comprising administering to a subject an effective amount of composition compnsmg:
a) a leucine (L)-amino acid entity chosen from L-leucine, oxo-leucine, -hydroxy-methylbutyrate (HMB), isovaleryl-CoA, or N-acetyl-leucine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
b) an arginine (R)-amino acid entity chosen from L-arginine, argininosuccinate, agmatine, creatine, or N-acetyl-arginine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
c) a glutamine (Q)-amino acid entity chosen from L-glutamine, carbamoyl-P, or N-acetyl-glutamine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
d) N-acetylcysteine (NAC) or a salt thereof, a dipeptide or salt thereof, or a combination of any of the aforesaid; and
e) an essential amino acid (EAA)-entity chosen from one, two, three, or four of:
i) a histidine (H)-amino acid-entity chosen from L-histidine, histidinol, histidinal, ribose-5-phosphate, carnosine, histamine, urocanate, or N-acetyl-histidine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
ii) a lysine (K)-amino acid-entity chosen from L-lysine, diaminopimelate, trimethyllysine, saccharopine, or N-acetyl-lysine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
iii) a phenylalanine (F)-amino acid-entity chosen from L-phenylalanine, phenylpyruvate, or N-acetyl-phenylalanine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid; or
iv) a threonine (T)-amino acid-entity chosen from L-threonine, oxo-butyrate, or N-acetyl-threonine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
wherein at least one of the leucine amino acid entity, the arginine amino acid, the glutamine amino acid entity, or one, two, three, or all of the EAA amino acid entities is a free amino acid,
wherein at least 50 wt. % of the total dry wt. of the composition is one or more amino acid entities in free form, and
wherein the total wt. % of (a)-(e) is greater than the total wt. % of other amino acid entities in the composition.
3. A method for improving muscle function, comprising administering to a subject an effective amount of a composition comprising:
a) a leucine (L)-amino acid entity chosen from L-leucine, oxo-leucine, -hydroxy-methylbutyrate (HMB), isovaleryl-CoA, or N-acetyl-leucine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
b) an arginine (R)-amino acid entity chosen from L-arginine, argininosuccinate, agmatine, creatine, or N-acetyl-arginine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
c) a glutamine (Q)-amino acid entity chosen from L-glutamine, carbamoyl-P, or N-acetyl-glutamine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
d) N-acetylcysteine (NAC) or a salt thereof, a dipeptide or salt thereof, or a combination of any of the aforesaid; and an essential amino acid (EAA)-entity chosen from one, two, three, or four of:
i) a histidine (H)-amino acid-entity chosen from L-histidine, histidinol, histidinal, ribose-5-phosphate, carnosine, histamine, urocanate, or N-acetyl-histidine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
ii) a lysine (K)-amino acid-entity chosen from L-lysine, diaminopimelate, trimethyllysine, saccharopine, or N-acetyl-lysine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
iii) a phenylalanine (F)-amino acid-entity chosen from L-phenylalanine, phenylpyruvate, or N-acetyl-phenylalanine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid; or
iv) a threonine (T)-amino acid-entity chosen from L-threonine, oxo-butyrate, or N-acetyl-threonine; or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
wherein at least one of the leucine amino acid entity, the arginine amino acid, the glutamine amino acid entity, or one, two, three, or all of the EAA amino acid entities is a free amino acid,
wherein at least 50 wt. % of the total dry wt. of the composition is one or more amino acid entities in free form, and
wherein the total wt. % of (a)-(e) is greater than the total wt. % of other amino acid entities in the composition.
4. The method of claim 1 , wherein the subject is experiencing one or more of sarcopenia, muscle deterioration, muscle decay, cachexia, drug-induced myopathy, muscular dystrophy, or myopenia.
5. The method of claim 1 , wherein the subject is experiencing a food deficiency selected from one or more of malnutrition, fasting; aging; autophagy; reduced protein synthesis; anabolic resistance; junction integrity; decreased mitochondrial biogenesis; and anaplerosis.
6. The method of claim 1 , wherein the composition is administered once daily, twice daily, or three times daily.
7. The method of claim 1 , wherein the subject has a rotator cuff injury.
8. The method of claim 1 , wherein the subject has a knee injury.
9. The method of claim 8 , wherein the composition is administered to the subject before or after a total knee arthroplasty.
10. The method of claim 1 , wherein the subject has a hip injury.
11. The method of claim 10 , wherein the composition is administered to the subject before or after a total hip arthroplasty.
12. The method of claim 1 , wherein the subject is an elderly subject.
13. The method of claim 1 , wherein the subject has chronic back pain; HIV; spinal cord injury; stroke; COPD; end-stage liver disease (ESLD), hepatic encephalopathy, variceal bleeding, portal hypertension, ascites, infection risk, sepsis, all-cause hospitalization, all-cause and liver-related mortality; or muscle weakness associated with aging.
14. The method of claim 1 , wherein the subject has diabetes or metabolic disease.
15. The method of claim 1 , wherein the subject has cancer.
16. The method of claim 15 , wherein the cancer is colorectal cancer or periampullary cancer.
17. The method of claim 1 , wherein administration of the composition to the subject results in a decrease in levels of one or more (e.g., all) of myoglobin, myostatin, GDF-11, cortisol-AM, C-reactive protein, insulin, or cytokines (e.g., one or more (e.g., all) ofiL-1A RBM, IL-1RA, IL-1 RI, IL-1 RII, IL-12, IL-18, or MCP-1) in the subject.
18. The method of claim 1 , wherein administration of the composition to the subject results in an increase in levels of one or more (e.g., all) of P3NP, IGF-1, IGFBP1, IGFBP3, FGF-21, DHEAS, or mTORC1 in the subject.
19. The method of claim 1 , wherein the subject is experiencing muscle weakness of one, two, or more (e.g., all) of skeletal muscle, cardiac muscle, or smooth muscle.
20. The method of claim 1 , wherein one, two, three, or more of methionine (M), tryptophan (W), valine (V), or cysteine (C) is absent from the composition, or if present, is present at less than 1 wt. %, 0.5 wt. %, or 0.1 wt. %.
21. The method of claim 1 , wherein the composition further comprises one or both of an isoleucine (1)-amino acid entity, chosen from L-isoleucine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-isoleucine, or a valine (V)-amino acid entity, chosen from L-valine or a salt thereof, or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-valine.
22. The method of claim 1 , wherein the wt. ratio of the L-amino acid entity, the R-amino acid entity, the Q-amino acid entity, and the NAC or salt thereof, or the dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC in the composition is, respectively, about 1-3:2-4:2-4:0.1-2.5.
23. The method of claim 1 , wherein at least one of (a)-(e) is in a salt form in the composition.
24. The method of claim 1 , wherein the composition comprises 5 to 15 different amino acid entities.
25. The method of claim 2 , wherein administering the composition to the subject activates muscle protein synthesis and reduces muscle protein wasting.